AOP-Wiki

API

All KERs

Showing 1376 to 1400 of 2767 KERs

ID	Upstream Event	Downstream Event	Creation Date	Last Updated	AOPs

3097	1765: Increase, Formation of DNA photoproducts	1461: Increase, DSB	Nov 16, 2023	Nov 16, 2023	1 AOP 331: Formation of DNA photoproducts leading to growth inhibition (1)
1345	1265: Increase, Ftz-f1 expression	988: Decrease, Circulating ETH	Feb 9, 2017	Feb 9, 2017	1 AOP 4: Ecdysone receptor agonism leading to incomplete ecdysis associated mortality
1462	1361: Increase, GABA	1359: Activate, GABA-A receptor	Apr 14, 2017	Apr 14, 2017	1 AOP 215: Molecular events lead to epilepsy
1885	1621: Increase, Gene expression	328: Decrease, Fecundity	Apr 22, 2019	Apr 22, 2019	None
1234	1175: Increase, Genes involved in fatty acid oxidation	209: Peptide Oxidation	Nov 29, 2016	Dec 3, 2016	None
1240	1175: Increase, Genes involved in fatty acid oxidation	1173: Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids	Nov 29, 2016	Dec 3, 2016	None
2226	1827: Increase, Global methylation	1365: Increase, Apoptosis	Dec 4, 2020	Dec 4, 2020	1 AOP 326: Thermal stress leading to population decline (3)
2885	2133: Increase, Glucuronidation of T4	961: Increased, Clearance of thyroxine from serum	Apr 12, 2023	Apr 12, 2023	None
2794	2070: Increase, Glycolysis	2071: Decrease, Glucose pool	Nov 1, 2022	Nov 1, 2022	1 AOP 267: Uncoupling of oxidative phosphorylation leading to growth inhibition via glucose depletion
2858	2117: Increase, goblet cell number	962: Increase, Mucin production	Mar 15, 2023	Mar 17, 2023	1 AOP 148: EGFR Activation Leading to Decreased Lung Function
2920	2137: Increase, Gonadotropins concentration in plasma	2138: Derease, testosterone levels	May 22, 2023	May 22, 2023	None
3212	2137: Increase, Gonadotropins concentration in plasma	1690: Decrease, testosterone levels	May 8, 2024	May 8, 2024	1 AOP 496: Androgen receptor agonism leading to reproduction dysfunction （in zebrafish）
1994	1698: Increase, hypermethylation of the promotor region of GnRHR	1699: Decease, expression of GnRHR	Oct 30, 2019	Oct 30, 2019	1 AOP 310: Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR
743	740: Increase, Hyperplasia (follicular cells)	741: Increase, Adenomas/carcinomas (follicular cell)	Nov 29, 2016	Dec 3, 2016	3 AOPs 110: Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) 119: Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse) 162: Enhanced hepatic clearance of thyroid hormones leading to thyroid follicular cell adenomas and carcinomas in the rat and mouse
783	782: Increase, Hyperplasia (forestomach epithelial cells)	779: Increase, Papillomas/carcinomas (squamous cells)	Nov 29, 2016	Dec 3, 2016	1 AOP 115: Epithelial cytotoxicity leading to forestomach tumors (in mouse and rat)
771	772: Increase, Hyperplasia (glandular epithelial cells of endometrium)	773: Increase, Endometrial adenocarcinomas	Nov 29, 2016	Dec 3, 2016	1 AOP 112: Increased dopaminergic activity leading to endometrial adenocarcinomas (in Wistar rat)
2972	772: Increase, Hyperplasia (glandular epithelial cells of endometrium)	1896: Genomic instability	Jul 27, 2023	Jul 27, 2023	1 AOP 503: Activation of uterine estrogen receptor-alfa leading to endometrial adenocarcinoma, via epigenetic modulation
731	744: Increase, Hyperplasia (Leydig cells)	745: Increase, Leydig cell tumors	Nov 29, 2016	Dec 3, 2016	2 AOPs 111: Decrease in androgen receptor activity leading to Leydig cell tumors (in rat) 120: Inhibition of 5α-reductase leading to Leydig cell tumors (in rat)
761	767: Increase, Hyperplasia (renal tubular cells)	713: Increase, Adenomas/carcinomas (renal tubular)	Nov 29, 2016	Dec 3, 2016	1 AOP 105: Alpha2u-microglobulin cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat)
728	735: Increase, Hyperplasia (terminal bronchiolar cells)	736: Increase, Adenomas/carcinomas (bronchioloalveolar)	Nov 29, 2016	Dec 3, 2016	1 AOP 109: Cytotoxicity leading to bronchioloalveolar adenomas and carcinomas (in mouse)
786	784: Increase, Hyperplasia (tubular epithelial cells)	713: Increase, Adenomas/carcinomas (renal tubular)	Nov 29, 2016	Dec 3, 2016	1 AOP 116: Cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat)
798	796: Increase, Hyperplasia (urothelial)	797: Increase, Adenomas/carcinomas (urothelial)	Nov 29, 2016	Dec 3, 2016	1 AOP 121: Urinary bladder calculi leading to urothelial papillomas and carcinomas (in mouse and rat)
2085	796: Increase, Hyperplasia (urothelial)	1763: carcinogenicity	Apr 21, 2020	Apr 21, 2020	1 AOP 335: AOP for urothelial carcinogenesis due to chemical cytotoxicity by mitochondrial impairment
1581	1343: Increase, hypertension	1226: Respiratory irritability	Jun 23, 2017	Jun 23, 2017	None
742	739: Increase, Hypertrophy and proliferation (follicular cell)	740: Increase, Hyperplasia (follicular cells)	Nov 29, 2016	Dec 3, 2016	3 AOPs 110: Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) 119: Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse) 162: Enhanced hepatic clearance of thyroid hormones leading to thyroid follicular cell adenomas and carcinomas in the rat and mouse

Key Event Relationships (KERs)

All KERs